

Correction of announced outcome of the exercise of warrants series TO 2

The board of directors of Amniotics AB (publ) (“Amniotics” or the “Company”) today announces, due to a technical error, corrected information on the outcome of the exercise period for warrants series TO 2 (the “Warrants”), which were announced on June 21, 2023, and issued in connection with the Company’s rights issue of units which was announced on December 20, 2022 (the “Rights Issue”). The correction entails that the subscription rate was approximately 90 per cent, instead of previously communicated 78 per cent, and Amniotics thereby receives approximately MSEK 5.5 before issue costs, instead of previously communicated MSEK 4.7.

In total, Amniotics issued 101,217,880 units in the Rights Issue, each consisting of one (1) share and one (1) Warrant. One (1) Warrant entitled the right to subscribe for one (1) new share in the Company at an exercise price of SEK 0.06 per share. The exercise period of the Warrants ran from and including June 5, 2023 to and including June 19, 2023. Corrected information of the final outcome shows that the subscription rate, after correction due to a technical error, amounted to approximately 90 per cent, meaning that 91,219,465 Warrants were utilized for subscription of the same amount of shares. Exercised Warrants has been replaced with interim shares pending registration with the Swedish Companies Registration Office. The interim shares are expected to be converted into shares during week 28, 2023.

Through the exercise of the Warrants the Company receives approximately MSEK 5.5 before issue costs. The total number of shares in Amniotics increases by 91,219,465, from 117,284,210 to 208,503,675. The share capital in Amniotics increases by SEK 4,933,982.312853, from SEK 6,343,801.925575 to SEK 11,277,784.238428.

Advisors

Vator Securities AB acts as financial advisor and issuer agent and Setterwalls Advokatbyrå AB acts as legal advisor to Amniotics in connection with the Rights Issue.

IMPORTANT INFORMATION

The information in this press release does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in Amniotics. Invitation to the persons concerned to subscribe for units consisting of shares and Warrants in Amniotics has only taken place through the prospectus that Amniotics published on February 17, 2023.

For more information please contact

Marcus Larsson
CEO, Amniotics AB
Phone: +46 (0) 763 0840 91
Email: ml@amniotics.com

About Amniotics

Amniotics AB (publ) is a clinical stage biotech company, developing innovative therapies, based on amniotic fluid derived stem cells. The company develops therapies to treat diseases where effective treatments are currently lacking.

Amniotics has an established GMP-facility, approved and licensed by the Swedish Medical Products Agency. The company has capabilities as a Contract Development and Manufacturing Organization (CDMO) for other biotech companies.

Amniotics is headquartered in Lund, Sweden.

The company is listed at Nasdaq First North Growth Market in Stockholm. Amniotics Certified Adviser at First North is Redeye AB.

Learn more at www.amniotics.com.

Attachments

[Correction of announced outcome of the exercise of warrants series TO 2](#)